Transneural

What Transneural does

Transneural Therapeutics, Inc. is a preclinical-stage biotechnology company developing a focused pipeline of novel small-molecule neuroplastogens intended to treat neuropsychiatric and neurodegenerative diseases. The company's core technology combines AI-engineered chemical scaffold design with applied medicinal chemistry to produce tailored receptor engagement at serotonin G-protein coupled receptors, specifically a dual 5-HT2A partial agonist and 5-HT2B antagonist profile. Lead candidate TN-001 is engineered to induce rapid structural neuroplasticity and synaptogenesis without hallucinogenic or dissociative effects and with a cardiac safety profile that supports chronic daily dosing. The pipeline consists of TN-001 and two additional undisclosed small-molecule programs, with initial indications targeting major depressive disorder (MDD) and post-traumatic stress disorder (PTSD) and broader expansion into other neuropsychiatric and neurodegenerative conditions with high unmet need. Transneural was founded in April 2025 as a spin-out of CaaMTech, a pharmaceutical drug discovery company focused on psychedelic-inspired medicines, and is headquartered in Issaquah, Washington under Delaware corporate law.

The company's business model is pharmaceutical drug development and eventual commercialization of prescription therapeutics, with future revenue dependent on FDA approval and downstream licensing or sale of approved products. Transneural has no commercial products, no pricing model, and no disclosed funding rounds; revenue is expected to follow traditional pharmaceutical development pathways, including potential milestone-based partnerships or licensing transactions once candidates reach clinical milestones. The go-to-market approach leverages deep CNS pharmaceutical expertise from leadership, including CEO Charmaine Lykins, who executed ten product launches across Karuna Therapeutics, MapLight Therapeutics, Acadia Pharmaceuticals, Lundbeck, Sunovion, and Eli Lilly, and Chief R&D Officer Mark A. Demitrack, MD, who led the NDA submission for duloxetine (Cymbalta) at Lilly and the clinical development of NeuroStar TMS at Neuronetics. Target patient segments are the approximately 21 million people in the United States with MDD and 13 million with PTSD, with a particular focus on the 30–50% of depressed patients and approximately 33% of PTSD patients who are treatment resistant to current therapies.

Name

Transneural

Legal name

Transneural Therapeutics, Inc.

Website

https://transneural.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

Transneural Therapeutics is a preclinical-stage biotechnology company developing AI-engineered neuroplastogen small molecules for neuropsychiatric and neurodegenerative diseases, with lead candidate TN-001 targeting treatment-resistant major depressive disorder and PTSD.

Ownership category

akta.pro rank

Product category

CNS Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy) (HLAAAMAB)

akta.pro secondary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

Keywords

• CNS drug development
• Preclinical biotechnology
• Neuroplastogen therapeutics
• Small molecule discovery
• Serotonergic receptor targeting

Headquarters

HQ city

Issaquah

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Drug Development and Commercialization: Transneural is a preclinical-stage biotechnology company. Revenue will be generated through the development and commercialization of novel neuroplastogen therapeutics. The company is developing a pipeline of small molecule drugs including lead asset TN-001 for MDD and PTSD. As a preclinical biotech, no commercial revenue currently exists.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Transneural is a preclinical-stage biotechnology company developing a focused pipeline of small-molecule neuroplastogens engineered on AI-designed chemical scaffolds to treat neuropsychiatric and neurodegenerative diseases. Lead asset TN-001 is a dual 5-HT2A partial agonist/5-HT2B antagonist designed to induce rapid antidepressant-associated neuroplasticity and synaptogenesis without hallucinogenic or dissociative effects, with a cardiac safety profile enabling chronic daily at-home dosing. The pipeline additionally includes two undisclosed small-molecule programs beyond TN-001.

Product overview

Transneural Therapeutics is a preclinical-stage biotechnology company developing a focused pipeline of novel rapid-acting neuroplastogens for neuropsychiatric and neurodegenerative diseases. The company's portfolio centers on lead asset TN-001, a dual 5-HT2A partial agonist/5-HT2B antagonist engineered on an AI-designed chemical scaffold, plus two additional undisclosed programs. All pipeline assets target G-protein coupled receptors (GPCRs) with tailored serotonergic receptor engagement designed to deliver rapid antidepressant efficacy without hallucinogenic effects. The company emerged from stealth in April 2025 and is progressing toward clinical trials.

Differentiator

Problem solved

Functional benefit

Products and services

• TN-001 TN-001 is Transneural's lead preclinical asset, a dual 5-HT2A partial agonist/5-HT2B antagonist small-molecule neuroplastogen designed on an AI-engineered chemical scaffold. It induces rapid structural neuroplasticity and synaptogenesis without hallucinogenic or dissociative effects, with a cardiac safety profile enabling chronic daily at-home dosing. It is being developed for major depressive disorder (MDD) and post-traumatic stress disorder (PTSD), targeting the substantial treatment-resistant patient population inadequately served by current therapies.
• Pipeline Programs (2 additional programs) Transneural's pipeline includes two additional small-molecule programs beyond lead asset TN-001, focused on novel rapid-acting agents for neuropsychiatric indications. Specific targets and indications for these programs have not yet been publicly disclosed, though all pipeline assets share the company's AI-engineered scaffold approach targeting GPCRs with tailored serotonergic receptor engagement.

Quantifiable outcome

• TN-001 rapidly induces statistically significant and dose-dependent structural neuroplasticity in rat neuronal cell culture assay, shown by increased number of neurons, synapses, and neurite network
• +4 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

Partnerships

One partnership is on record.

• CaaMTechfoundationalStrategic or Co-development Partner · 22 April 2025Transneural is a spin-out of CaaMTech, a pharmaceutical drug discovery company utilizing a collaborative scientific approach to engineer novel small-molecule psychedelic-inspired medicines to treat mental health conditions. CaaMTech's research and discovery capabilities in psychedelic-inspired medicines provided the foundation for Transneural's formation and initial technology platform.

Scale indicators2 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• MapLight Therapeutics: MapLight Therapeutics is a clinical-stage CNS biopharma developing targeted therapies for schizophrenia and other neuropsychiatric disorders, sharing Transneural's CNS focus, mechanistic precision-medicine approach, and prior C-suite leadership (Lykins served as CCO at MapLight).
• GH Research: GH Research is developing mebufotenin, a potent 5-HT2A agonist, for treatment-resistant depression, sharing the same serotonergic neuroplastogen mechanism and MDD focus as Transneural, though pursued via an inhalable psychedelic rather than a non-hallucinogenic oral molecule.
• Compass Pathways: Compass Pathways is developing psilocybin therapy for treatment-resistant depression, a directly overlapping indication and mechanism class (5-HT2A-mediated neuroplasticity) as Transneural's TN-001, positioning both as non-SSRI options for the same patient population.
• Cybin: Cybin is developing deuterated psilocybin analogs and other 5-HT2A-targeting neuroplastogens for MDD and anxiety disorders, sharing Transneural's core thesis that engineered serotonergic molecules can deliver durable antidepressant effects with improved safety/dosing profiles.
• atai Life Sciences: atai Life Sciences is a clinical-stage biopharma building a pipeline of psychedelic and psychedelic-inspired therapies for depression, PTSD, and other mental health conditions, overlapping Transneural's therapeutic area and mechanism rationale (5-HT2A/neuroplasticity) but with a broader, asset-collecting model.
• MindMed: MindMed is developing psychedelic-inspired medicines (e.g., MM-120 for anxiety disorders) targeting 5-HT2A and related CNS receptors, directly comparable to Transneural's strategy of engineering serotonergic neuroplastogens for psychiatric indications.

Broad incumbents

• Johnson & Johnson (Spravato): J&J markets Spravato (esketamine), the only FDA-approved NMDA/5-HT-targeting rapid-acting antidepressant for treatment-resistant depression, representing the incumbent benchmark that Transneural's non-hallucinogenic, daily-dosed TN-001 would compete against if approved.
• Sage Therapeutics: Sage Therapeutics is a CNS-focused biopharma with Zurzuvae (zuranolone) for postpartum depression and other GABAergic modulators in development, comparable as a focused CNS innovator pursuing novel mechanisms for treatment-resistant depression rather than a psychedelic-based approach.
• Karuna Therapeutics (Bristol Myers Squibb): Karuna developed KarXT/COBENFY (xanomeline/trospium), a muscarinic agonist for schizophrenia that was acquired by Bristol Myers Squibb for ~$14B; its leadership alumni (including Transneural CEO Charmaine Lykins) and similar CNS strategy of replacing dopaminergic/serotonergic drugs with targeted receptor modulators make it highly comparable.

Emerging players

• Neumora Therapeutics: Neumora Therapeutics is a clinical-stage neuroscience company developing precision neuropsychiatric therapies including NMRA-140 (a 5-HT2A inverse agonist) for MDD, making it a close peer in target, indication, and emerging-stage profile to Transneural.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/transneural

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Transneural